THE RESEARCH, WITH ITS CONTEXT
What was measured? Who was studied? What remains uncertain? Start with a short explanation, then follow the original paper.
Starting collection · source checks through October 13, 2026 · not an exhaustive review
START HERE · OCTOBER 18, 2026
A plain-language introduction to the human research, with a deeper look at the study details.
01 — HUMAN EVIDENCE
A biomarker is a measured biological signal. A functional outcome measures something a person can do. Keep those meanings separate.
BAYLOR RANDOMIZED TRIAL · 2023 ISSUE
The older placebo group helps assess treatment effects. The younger baseline is a reference; a similar laboratory level does not establish a younger biological age.
Recruitment totals; some tests used fewer samples. Younger adults also received GlyNAC for two weeks. Original trial, Tables 1–3 ↗
BIOMARKER · MUSCLE SAMPLE
A cellular antioxidant involved in managing oxidative stress.
Placebo recipients did not improve. A tissue measurement is not a direct measure of age or proof of longer life.
BIOMARKER · PLASMA
A marker of oxidation of fats, one aspect of oxidative stress.
Placebo recipients did not improve. A change in one marker alone does not establish disease prevention.
BIOMARKER · BLOOD
An immune-signalling protein, used here as an inflammation marker.
A lower inflammation-marker value does not by itself demonstrate improved protection against infection.
These explanations describe one small trial with selected participants and multiple outcomes. The human-study overview also includes an open-label pilot and a larger, shorter trial that did not meet its primary endpoint.
Compare tested amounts and label directions ↗MECHANISMS · THREE DIFFERENT EVIDENCE CONTEXTS
A mechanistic hypothesis can be useful without being a confirmed explanation. Follow what each experiment actually measured.
Baylor’s 16-week randomized trial reported increased mitochondrial fatty-acid oxidation in the treated older group. HOMA-IR improved, while fasting glucose and glucose tolerance did not.
PINK1 protein expression increased; the LC3AB autophagy-marker change was not significant. Exploratory protein measurements used three participants per group and do not establish cellular recycling flux.
CoA restoration and mTOR mediation were not demonstrated in this trial.
Kumar et al. · original trial ↗Lai et al. 2012 studied 36 people with SLE for three months: nine active recipients and three placebo recipients in each dose cohort. NAC increased T-cell mitochondrial membrane potential (Δψm; p = 0.0001) while reducing mTOR signaling.
Important clinical analyses pooled 2.4 and 4.8 g/day; 1.2 g/day did not improve disease-activity scores. All nine active recipients at 2.4 g/day completed treatment. At 4.8 g/day, three of nine had intolerance involving heartburn, nausea/vomiting or headaches.
mTOR activity was assessed using phosphorylated S6 ribosomal protein (pS6-RP). Figure 4 pooled all three NAC doses. It does not establish a 2.4 g cutoff, or show that lowering mitochondrial membrane potential caused the effect. This was a disease-specific NAC trial, not a GlyNAC aging trial.
Jouandin et al. 2022 traced lysosomal cystine mobilization into cysteine and Coenzyme A (CoA). Changes in mitochondrial carbon flow helped maintain low TORC1 activity and autophagy during fasting.
CoA participates in fatty-acid β-oxidation and other fuel pathways. The precise contribution of fat versus other substrates to acetyl-CoA in these experiments remained unresolved.
These were fly tissue, nutrient-state and genetic experiments, not oral NAC or GlyNAC treatment in humans. “Coping with starvation” discusses this same study; it is not a second experiment.
Jouandin et al. · Science ↗02 — ANIMAL EVIDENCE
Species and intervention come first. GlyNAC, NAC alone and glycine alone are different experiments, with different outcome measures.
Mean lifespan is the arithmetic average; median lifespan is the midpoint of survival. Neither is the longest lifespan observed. Survival after an acute disease challenge is another outcome again.
104.0 → 128.6 weeks · mean total lifespan
23.7% higher in the supplemented group.
Male survival improved
Female survival did not significantly improve.
3.7% / 6.2% female / male · pooled median lifespan
Three-site Interventions Testing Program.
Each card describes the original experiment. Feed and drinking-water concentrations are not daily body-weight doses. Animal regimens are not human dosing instructions, and none of these studies establishes the effectiveness of a linked retail product.
READ THE PAPER. KEEP THE CONTEXT.